SHRXF

Sharp Therapeutics Corp. is a preclinical therapeutics company engaged in the discovery and development of small-molecule therapies for the treatment of genetic diseases. It uses a collection of platform technologies to discover compounds that can restore the function lost in mutation, thus restoring the patient to normality. The components of this technology platform are the CoreX assay technology, which enables measurements of the loss-of-function associated with gene mutation in a particular disease; the AlloChem Compound Libraries, that have been curated from commercial compound libraries for their ability to bind the target protein in an allosteric manner, thus increasing its stability and activity at the same time, and the Mine data system and machine learning layer, which combines data from various compounds and programs to provide models for what compounds should be made during medicinal chemistry and to improve the data quality of the signals coming from the CoreX assays.